This is a news story, published by Home, that relates primarily to MindBio Therapeutics news.
For more mental health treatments news, you can click here:
more mental health treatments newsFor more news from Home, you can click here:
more news from HomeOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
drug MB22001. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest sustained antidepressant response news, antidepressant response news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
MindBio TherapeuticsHome
•76% Informative
MindBio Therapeutics has announced its drug MB22001 has reduced symptoms of depression in a Phase IIa trial.
One month post-cessation of treatment, the antidepressant response was sustained with a 65% reduction in depressive symptoms.
The trial also showed substantial improvements in mood, energy, creativity, well-being, depression and sleep.
VR Score
64
Informative language
56
Neutral language
55
Article tone
formal
Language
English
Language complexity
56
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
9
Source diversity
3
Affiliate links
no affiliate links